Mollie Leoni

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations

Alan L. Ho, Irene Braña, Robert I. Haddad et al. · Journal of Clinical Oncology · 2021 · 196 citations · Full text

Medicine, Oncology, Pharmacology +13

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Harry P. Erba, Amir T. Fathi, Ghayas C. Issa et al. · Blood · 2022 · 71 citations

Medicine, Pharmacology, Pharmacotherapy +13

Mogamulizumab <i>versus</i> investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Adrienne A. Phillips, Paul Fields, Olivier Hermine et al. · Haematologica · 2018 · 68 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

Pierluigi Porcu, Stacie Hudgens, Pietro Quaglino et al. · Clinical Lymphoma Myeloma & Leukemia · 2020 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +16